NEXIMMUNE INC (NEXI)
US65344D2080 - Common Stock
We assign a fundamental rating of 2 out of 10 to NEXI. NEXI was compared to 568 industry peers in the Biotechnology industry. NEXI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEXI is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year NEXI has reported negative net income.
In the past year NEXI has reported a negative cash flow from operations.
NEXI had negative earnings in each of the past 5 years.
NEXI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
NEXI's Return On Assets of -287.63% is on the low side compared to the rest of the industry. NEXI is outperformed by 94.09% of its industry peers.
With a Return On Equity value of -871.66%, NEXI is not doing good in the industry: 82.61% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -287.63% | ||
| ROE | -871.66% | ||
| ROIC | N/A |
ROA(3y)-164.95%
ROA(5y)-153.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for NEXI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for NEXI has been increased compared to 1 year ago.
NEXI has more shares outstanding than it did 5 years ago.
NEXI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -43.67, we must say that NEXI is in the distress zone and has some risk of bankruptcy.
NEXI's Altman-Z score of -43.67 is on the low side compared to the rest of the industry. NEXI is outperformed by 94.61% of its industry peers.
There is no outstanding debt for NEXI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -43.67 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 1.30 indicates that NEXI should not have too much problems paying its short term obligations.
NEXI's Current ratio of 1.30 is on the low side compared to the rest of the industry. NEXI is outperformed by 85.04% of its industry peers.
NEXI has a Quick Ratio of 1.30. This is a normal value and indicates that NEXI is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.30, NEXI is not doing good in the industry: 82.96% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 1.3 |
3. Growth
3.1 Past
The earnings per share for NEXI have decreased strongly by -245.95% in the last year.
EPS 1Y (TTM)-245.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, NEXI will show a very strong growth in Earnings Per Share. The EPS will grow by 25.96% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.01%
EPS Next 2Y41.34%
EPS Next 3Y25.96%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
NEXI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NEXI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NEXI's earnings are expected to grow with 25.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.34%
EPS Next 3Y25.96%
5. Dividend
5.1 Amount
NEXI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEXIMMUNE INC
NASDAQ:NEXI (7/11/2024, 8:02:56 PM)
After market: 3.45 -0.48 (-12.21%)3.93
+1.62 (+70.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.79%
Inst Owner Change-93.17%
Ins Owners280.8%
Ins Owner Change0%
Market Cap5.38M
Analysts82.86
Price Target2.04 (-48.09%)
Short Float %0.02%
Short Ratio0
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.81 | ||
| P/tB | 1.81 | ||
| EV/EBITDA | N/A |
EPS(TTM)-66.25
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-15.75
FCFYN/A
OCF(TTM)-15.74
OCFYN/A
SpS0
BVpS2.17
TBVpS2.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -287.63% | ||
| ROE | -871.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-164.95%
ROA(5y)-153.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0.99% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 1.3 | ||
| Altman-Z | -43.67 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)178.7%
Cap/Depr(5y)258.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-245.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.25%
EPS Next Y99.01%
EPS Next 2Y41.34%
EPS Next 3Y25.96%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.07%
OCF growth 3YN/A
OCF growth 5YN/A